These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 20372113

  • 21. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
    Berković MC, Altabas V, Herman D, Hrabar D, Goldoni V, Vizner B, Zjacić-Rotkvić V.
    Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
    [Abstract] [Full Text] [Related]

  • 22. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC, Lygidakis NJ, Toubanakis C, Pavlatos S, Tseleni-Balafouta S, Giannatou E, Mallas E, Safioleas M.
    Hepatogastroenterology; 2005 Jun; 52(63):731-41. PubMed ID: 15966194
    [Abstract] [Full Text] [Related]

  • 23. Chromogranin A: is it a useful marker of neuroendocrine tumors?
    Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P.
    J Clin Oncol; 2007 May 20; 25(15):1967-73. PubMed ID: 17513802
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R, Libutti SK, Saif MW.
    JOP; 2013 Mar 10; 14(2):155-7. PubMed ID: 23474561
    [Abstract] [Full Text] [Related]

  • 27. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
    Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M.
    Neuroendocrinology; 2017 Mar 10; 104(2):170-182. PubMed ID: 27078712
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.
    Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M.
    Ann Surg Oncol; 2010 Sep 10; 17(9):2427-43. PubMed ID: 20217257
    [Abstract] [Full Text] [Related]

  • 30. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors.
    Kim M, Lee S, Lee J, Park SH, Park JO, Park YS, Kang WK, Kim ST.
    Cancer Res Treat; 2016 Jan 10; 48(1):153-61. PubMed ID: 25779359
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.
    Panzuto F, Severi C, Cannizzaro R, Falconi M, Angeletti S, Pasquali A, Corleto VD, Annibale B, Buonadonna A, Pederzoli P, Delle Fave G.
    J Endocrinol Invest; 2004 Jan 10; 27(1):6-11. PubMed ID: 15053236
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K, Binderup T, Langer SW, Kjaer A, Knigge P, Grøndahl V, Melchior L, Federspiel B, Knigge U.
    BMC Cancer; 2020 Jan 10; 20(1):27. PubMed ID: 31924180
    [Abstract] [Full Text] [Related]

  • 37. The Role of the Acute Octreotide Suppression Test in Detecting Patients with Neuroendocrine Neoplasms.
    Kruljac I, Vičić I, Blaslov K, Kolak Z, Benković M, Kust D, Ladika Davidović B, Tometić G, Penavić I, Dabelić N, Vazdar L, Pavić T, Vrkljan M.
    Neuroendocrinology; 2018 Jan 10; 107(3):284-291. PubMed ID: 30114698
    [Abstract] [Full Text] [Related]

  • 38. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
    Jilesen AP, Busch OR, van Gulik TM, Gouma DJ, Nieveen van Dijkum EJ.
    Dig Surg; 2014 Jan 10; 31(6):407-14. PubMed ID: 25572908
    [Abstract] [Full Text] [Related]

  • 39. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
    Modlin IM, Drozdov I, Alaimo D, Callahan S, Teixiera N, Bodei L, Kidd M.
    Endocr Relat Cancer; 2014 Aug 10; 21(4):615-28. PubMed ID: 25015994
    [Abstract] [Full Text] [Related]

  • 40. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
    Corsello A, Di Filippo L, Massironi S, Sileo F, Dolcetta Capuzzo A, Gemma M, Carlucci C, Cusini C, Colombo B, Dallatomasina A, Franchi GM, Corti A, Manzoni MF.
    PLoS One; 2018 Aug 10; 13(5):e0196858. PubMed ID: 29723285
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.